Aug 7, 2015 - May 15, 2013 - Radium-223 is indicated for the treatment of patients with castration-resistant )www-pub.iaea.org/MTCD/Publications/PDF/Pub1578_web-57265295.pdf. Radium-223 is a radiopharmaceutical localizing to bone and is approved for treatment of bone metastases in prostate cancer. Safety and efficacy data regarding PDF | Purpose: Radium Ra 223 dichloride (radium-223, Xofigo®) is the first targeted alpha therapy for patients with castration-resistant prostate | Find, read Jan 6, 2020 -Xofigo® is the brand name of a radiopharmaceutical, Radium 223 dichloride. Ra-. 223 has a half-life of 11.4 days and emits alpha, beta, and gamma radiation. Feb 6, 2019 - Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. 2 Abstract. Radium-223 dichloride (radium-223) was approved for the treatment of patients with accessdata.fda.gov/drugsatfda_docs/label/2013/203971lbl.pdf.